Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Seattle Genetics Inc. (NasdaqNM:SGEN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider
Location
21823 30th Drive SE
Bothell, WA 98021
Phone: (425) 527-4000
Fax: (425) 489-4798
Employees (last reported count): 46
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 76%
·Over the last 6 months:
 · 2 insider buys; 820.0K shares (3.8% of insider shares)
·Institutional: 40% (168% of float)
(33 institutions)
·Net Inst. Selling: 727.0K shares (+6.59%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Seattle Genetics, Inc. (SGEN) discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. SGEN has four monoclonal antibody-based technologies: monoclonal antibodies; monoclonal antibodies chemically linked to cell-killing drugs, or monoclonal antibody-drug conjugates; single proteins containing monoclonal antibody and toxin components, or single-chain immunotoxins; and antibody-directed enzyme prodrug therapy (ADEPT). The Company's technologies enable it to increase the potency and efficacy of monoclonal antibodies that have specificity for cancer or related diseases but are not potent enough on their own. SGEN has constructed a diverse portfolio of drug candidates targeted to many types of human cancer. The Company's four technologies provide it with the means to discover and develop monoclonal antibody-based drug candidates internally as well as to partner its technology with other companies also developing monoclonal antibodies.
More from Market Guide: Expanded Business Description

Financial Summary
Seattle Genetics Inc. discovers and develops monoclonal antibody based drugs to treat cancer and related diseases. SGEN has four mAb-based technologies: engineered mAbs; mAb-drug conjugates; single-chain immunotoxins; and antibody-directed enzyme prodrug theragy. For the six months ended 6/30/01, revenues fell 38% to $35 thousand. Net loss applicable to Common totalled $9.4 million, up from $2.1 million. Results reflect the absence of government grants and an increase in R&D expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Charles Waite, Jr., 45
Chairman
--  
H. Perry Fell, Ph.D., 43
CEO, Director
$240K
Clay Siegall, Ph.D., 40
Pres, CSO
240K
Tim Carroll, 49
CFO
81K
Morris Rosenberg
VP, Devel.
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SGENAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Mar-2001
$4.375
Recent Price$5.72 
52-Week High
on 7-May-2001
$11.49 
Daily Volume (3-month avg)61.7K
Daily Volume (10-day avg)28.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
13-Week Change-34.3%
13-Week Change
relative to S&P500
-27.0%
Share-Related Items
Market Capitalization$167.6M
Shares Outstanding29.3M
Float7.00M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.36 
Earnings (ttm)-$2.45 
Earnings (mrq)-$0.18 
Sales (ttm)$0.01 
Cash (mrq)$1.49 
Valuation Ratios
Price/Book (mrq)2.42 
Price/EarningsN/A 
Price/Sales (ttm)821.48 
Income Statements
Sales (ttm)$78.0K
EBITDA (ttm)-$12.3M
Income available to common (ttm)-$15.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-28.76%
Return on Equity (ttm)-49.16%
Financial Strength
Current Ratio (mrq)11.81 
Debt/Equity (mrq)0 
Total Cash (mrq)$43.6M
Short Interest
As of 8-Aug-2001
Shares Short206.0K
Percent of Float2.9%
Shares Short
(Prior Month)
214.0K
Short Ratio4.48 
Daily Volume46.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.